Use of Glycoprotein IIb-IIIa Inhibitors in patients undergoing Carotid Artery Stenting

Antiplatelet therapies with thromboxane inhibitors and adenosine 5'-diphosphate antagonists have been widely used following carotid artery stenting (CAS). These therapies may not be applicable in patients that are intolerant or nonresponders. Glycoprotein IIb/IIIa inhibitors (GPI) are a proposed alternative therapy for these patients, however, it’s use has been limited owing to concern of increased hemorrhage. Thus, the purpose of this study is to assess the safety profile of GPI in patient’s undergoing transfemoral CAS (TF-CAS) and transcarotid artery revascularization using flow reversal (TCAR).